Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar

📆 8/8/2024 8:33 pm
📰 Forbes

⏱ Reading Time:
9 sec. here
11 min. at publisher
📊 Quality Score:
News: 38%
Publisher: 53%

Eli Lilly News

Novo Nordisk,Tirzepatide,Zepbound

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts’ expectations in the face ofEli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for the second quarter of 2024.

Lilly reported $3.28 earnings per share, besting expectations of $2.74, and raised the range of its annual forecast $2.05 to earnings per share between $15.10 to $15.60.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Write Comment

Singapore Singapore Latest News, Singapore Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales SoarRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: ForbesTech - 🏆 318. / 59 Read more »